Short answer
Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Upcoming November 6, 2026 poster presentation at HCMS during American Heart Association Scientific Sessions 2026.
Atrium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Upcoming November 6, 2026 poster presentation at HCMS during American Heart Association Scientific Sessions 2026
- Investor relevance: conference data may influence clinical-development expectations and Atrium’s valuation
- Updated corporate presentation available through Atrium’s Investors/Media webpage
Item 8.01 · Other Events
- New mouse-model data to be presented November 6, 2026, at AHA Scientific Sessions in Chicago
- Single-dose mATR 1072 reversed cardiac glycogen accumulation after established disease in mice
- Improvements in cardiac hypertrophy and ECG abnormalities strengthen ATR 1072’s preclinical rationale
- Investor significance: supportive animal data for PRKAG2 syndrome, but human efficacy remains unvalidated
Item EX-99.1 · Exhibit EX-99.1
- Atrium will present preclinical ATR 1072 data at AHA Scientific Sessions on November 6, 2026
- Mouse surrogate mATR 1072 reversed cardiac glycogen accumulation and improved hypertrophy and ECG abnormalities
- Findings support ATR 1072’s disease-modifying rationale, but remain animal-model evidence with no demonstrated human efficacy
- Ongoing Phase 1/2 Corventis trial targets approximately 37 participants, with initial proof-of-concept data expected in the second half of 2027
- PRKAG2 syndrome has an estimated 1,000 to 2,000 US patients and no approved therapy addressing its genetic cause
Item EX-99.2 · Exhibit EX-99.2
- Investor presentation outlines Atrium’s post-launch progress since February 2026, including ATR 1072 trial clearance and first patient dosing
- ATR 1072 Phase 1/2 Corventis trial targets PRKAG2 syndrome, with approximately 37 participants and initial proof-of-concept data expected in 2H 2027
- ATR 1086 targets PLN cardiomyopathy, with IND-enabling studies initiated in 2026 and an IND filing anticipated in 2027
- Cash, cash equivalents and investments totaled $264M as of June 30, 2026, supporting projected runway through end of 2028
- Pipeline includes $1.5B in potential R&D milestone payments from existing BMS and LLY collaborations, subject to agreement conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atrium Therapeutics, Inc. 8-K filings
Get the next RNA 8-K as it lands
Follow RNA for push alerts, or ask the research agent what this filing means.